NEW ZEALAND DATA SHEET - Medsafe

Madopar (levodopa) Data Sheet (DS) - Medsafe

MADOPAR 160202 1 Data Sheet MADOPAR® Levodopa + benserazide Capsules 62.5, 125 and 250; dispersible tablet 62.5; HBS modified-release capsule 125

  Levodopa, Dispersible

Section 1: Legislation - Medsafe Home Page

Section 2: Overview of Regulation of Clinical Trials in New Zealand . Section summary Under Section 30 of the Medicines Act 1981, approval from the Director-General of

  Section, Clinical, Legislation, Section 1

Section 1: Legislation relating to the labelling - …

Part 5, Ed 1.6 Page 2 of 18 . Section 1: Legislation relating to the labelling of medicines and related products Section summary This section lists the legislation regulating the labelling of medicines and related products.

  Section, Relating, Legislation, Labelling, Section 1, Legislation relating to the labelling

NEW ZEALAND DATA SHEET VERMOX® - …

NEW ZEALAND DATA SHEET VERMOX® Vermox® Page 2 of 7 For control of enterobiasis Adults and children 2-12 years: 1 Vermox tablet (100 mg) or 5 mL of suspension (100 mg) is given.

Guideline on the Regulation of Therapeutic …

Guideline on the Regulation of Therapeutic Products in New Zealand Part 10: Requirements for information for prescribers and consumers Edition 7.0

  Guidelines, Product, Regulations, Therapeutic, Guideline on the regulation of therapeutic, Guideline on the regulation of therapeutic products in

Clonazepam: oral drops (2.5 mg/ml); injection (1 mg).

2. you have severe and chronic lung disease 3. you have severe liver disease 4. you have an addiction to drugs or alcohol 5. the package is torn or shows signs of tampering

  Clonazepam

NEW ZEALAND DATA SHEET - Medsafe

NEW ZEALAND DATA SHEET 5 Hypnovel 170717 Medical history of alcohol or drug abuse Hypnovel should be avoided in patients with a medical history of alcohol or drug abuse.

  Drug

SCHEDULE OF FEES (effective from 1 July 2018)

Page 1 of 10. SCHEDULE OF FEES (effective from 1 July 2018) • All fees listed are GST inclusive. • More detailed descriptions of the type of application or change to which a fee applies can be

  Schedule, Effective, Fees, Schedule of fees

Nortriptyline (as hydrochloride) 10 mg and 25 mg Tablets

1 Nortriptyline NRIM 09052013 NEW ZEALAND DATA SHEET Nortriptyline NRIM . Nortriptyline (as hydrochloride) 10 mg and 25 mg Tablets . This product may not be interchangeable with similar products on the New Zealand market

2. QUALITATIVE AND QUANTITATIVE COMPOSITION 3 ...

1. PRODUCT NAME LOSARTAN ACTAVIS (Losartan Potassium 12.5mg, 25mg, 50mg and 100mg Tablets) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains: 12.5 mg losartan potassium 25 mg losartan potassium 50 mg losartan potassium 100mg losartan potassium . For the full list of excipients, see section 6.1. 3. …

  Product, Name, Qualitative, Losartan, Product name losartan

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

3 Bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum -sensitive

  Carboplatin

Chemotherapy Sequencing Guide – For therapies …

Bevacizumab Bleomycin Carboplatin Cisplatin Cyclophosphamide Cytarabine Dacarbazine Docetaxel Doxorubicin Epirubicin Etoposide Fludarabine Fluorouracil Gemcitabine Ifosfamide Irinotecan Leucovorin Liposomal Oxaliplatin Methotrexate Mitomycin Paclitaxel Pemetrexed Pralatrexate Topotecan Vincristine Vinorelbine

  Guide, Sequencing, Therapies, Chemotherapy, Carboplatin, Chemotherapy sequencing guide for therapies

Clinical trials appendix Q1 2018 Results update

Ovarian cancer and other cancers 10 Lynparza(PARP inhibitor) Trial Population Patients Design Endpoints Status Phase III SOLO-2 NCT01874353 Platinum-sensitive recurrent

  Recurrent

Opdivo® (nivolumab) Injectable Medication …

Opdivo ® (nivolumab) Injectable Medication Precertification Request . Page 3 of 3 (All fields must be completed and legible for Precertification Review.)

  Medication, Request, Precertification, Nivolumab, Injectable medication precertification request, Injectable, Injectable medication

HIGHLIGHTS OF PRESCRIBING INFORMATION …

3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Melanoma KEYTRUDA®(pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic ...

  Pembrolizumab